Astellas, through its subsidiary in the
Adding Nanna's proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters Astellas' early stage drug development capabilities. Nanna's unique capabilities enable the creation and rapid testing of more diverse chemical libraries. The approach enables phenotype-based screening which is not feasible with conventional DELs. It can also be applied to various assay systems including cell-based assays utilizing patient-derived cells, potentially enabling screens that are tailored to a specific disease biology.
'We believe this acquisition will enable us to create new solutions that address unmet medical needs by combining Nanna's unique technology platform with our research and development capabilities related to mitochondrial diseases,' said
'We are focused on developing innovative modulators of mitochondria. This critical organelle, the center of energy production and signaling in almost every cell, is implicated in numerous human diseases' said
Consideration for the acquisition,
The impact of this transaction on Astellas' financial results for the fiscal year ending
About Astellas
About Nanna
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contact:
Tel: +81-3-3244-3201
Fax: +81-3-5201-7473
(C) 2020 Electronic News Publishing, source